Karim Rihawi

机构：Azienda USL di Bologna, Istituti di Ricovero e Cura a Carattere Scientifico · ORCID：0000-0002-3915-466X

发表论文 91 篇 · 总被引 1410 次 · h-index 22

代表论文

• Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications (2021 · International Journal of Molecular Sciences · 被引 173)
• Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience (2022 · ESMO Open · 被引 35)
• The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer (2022 · Journal of Experimental & Clinical Cancer Research · 被引 26)
• Automated Prediction of the Response to Neoadjuvant Chemoradiotherapy in Patients Affected by Rectal Cancer (2022 · Cancers · 被引 16)
• A phase II, Open-Label, Single-Arm Trial of Carboplatin Plus Etoposide with Bevacizumab and Atezolizumab in Patients with Extended-Stage Small-Cell Lung Cancer (CeLEBrATE study): Background, Design and Rationale (2022 · Future Oncology · 被引 7)
• Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study (2025 · Journal for ImmunoTherapy of Cancer · 被引 6)